Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

This study is currently recruiting participants.

Study NCT00265798 Information provided by National Cancer Institute (NCI)

First Received: December 14, 2005 Last Updated: July 7, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	July 2006 (Final data collection date for primary outcome measure)

Publications:

Nimeiri HS, Maki RG, Kasza K, et al.: Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-7, 2008.